A Randomized Controlled Study on the Effects of Bisoprolol and Atenolol on Sympathetic Nervous Activity and Central Aortic Pressure in Patients with Essential Hypertension

PLoS ONE

Volumn 8, Issue 9, 2013, Pages

  Zhou, Wei Jun ^a,b,c   Wang, Ren Ying ^a,b   Li, Yan ^a,b   Chen, Dong Rui ^a,b   Chen, Er Zhen ^a   Zhu, Ding Liang ^a,b   Gao, Ping Jin ^a,b,c  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b Shanghai Institute of Hypertension   (China)

^c Chinese Academy of Sciences   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ATENOLOL; BISOPROLOL; BISOPROLOL FUMARATE;

ADULT; AGED; ANALYTICAL EQUIPMENT; AORTA PRESSURE; ARTICLE; AUTONOMIC NERVOUS SYSTEM FUNCTION; BLOOD PRESSURE REGULATION; CENTRAL AORTIC PRESSURE; CENTRAL SYSTOLIC BLOOD PRESSURE; CONTROLLED STUDY; DRUG EFFECT; ESSENTIAL HYPERTENSION; FEMALE; FINOMETER; HEART RATE VARIABILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; PRESSORECEPTOR REFLEX; PROSPECTIVE STUDY; PULSE WAVE; RANDOMIZED CONTROLLED TRIAL; SYMPATHETIC NERVOUS ACTIVITY; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION;

ADULT; ANTIHYPERTENSIVE AGENTS; ARTERIAL PRESSURE; ATENOLOL; BAROREFLEX; BISOPROLOL; FEMALE; HEART RATE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84883777988     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0072102     Document Type: Article

References (49)

1. Julius S, Schork N, Schork A, (1988) Sympathetic hyperactivity in early stages of hypertension: the Ann Arbor data set. J Cardiovasc Pharmacol 12 Suppl 3: S121-129.
2. Smith PA, Graham LN, Mackintosh AF, Stoker JB, Mary DA, (2004) Relationship between central sympathetic activity and stages of human hypertension. Am J Hypertens 17 (3) (): 217-222.
3. Aksamit TR, Floras JS, Victor RG, Aylward PE, (1987) Paroxysmal hypertension due to sinoaortic baroreceptor denervation in humans. Hypertension 9 (3) (): 309-314.
4. Liu HK, Guild SJ, Ringwood JV, Barrett CJ, Leonard BL, et al. (2002) Dynamic baroreflex control of blood pressure: influence of the heart vs. peripheral resistance. Am J Physiol Regul Integr Comp Physiol 283 (2) (): R533-542.
5. Imholz BP, Wieling W, van Montfrans GA, Wesseling KH, (1998) Fifteen years experience with finger arterial pressure monitoring: assessment of the technology. Cardiovasc Res 38 (3) (): 605-616.
6. Malik M, (1996) Heart rate variability: standards of measurement, physiological interpretation and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Circulation 93 (5) (): 1043-1065.
7. Parati G, Di Rienzo M, Mancia G, (2000) How to measure baroreflex sensitivity: from the cardiovascular laboratory to daily life. J Hypertens 18 (1) (): 7-19.
8. Vaishnav S, Stevenson R, Marchant B, Lagi K, Ranjadayalan K, et al. (1994) Relation between heart rate variability early after acute myocardial infarction and long-term mortality. Am J Cardiol 73 (9) (): 653-657.
9. Kleiger RE, Miller JP, Bigger JT Jr, Moss AJ, (1987) Decreased heart rate variability and its association with increased mortality after acute myocardial infarction. Am J Cardiol 59 (4) (): 256-262.
10. La Rovere MT, Pinna GD, Hohnloser SH, Marcus FI, Mortara A, et al. (2001) Baroreflex sensitivity and heart rate variability in the identification of patients at risk for life-threatening arrhythmias: implications for clinical trials. Circulation 103 (16) (): 2072-2077.
11. Safar ME, Blacher J, Pannier B, Guerin AP, Marchais SJ, et al. (2002) Central pulse pressure and mortality in end-stage renal disease. Hypertension 39 (3) (): 735-738.
12. Nurnberger J, Keflioglu-Scheiber A, Opazo Saez AM, Wenzel RR, Philipp T, et al. (2002) Augmentation index is associated with cardiovascular risk. J Hypertens 20 (12) (): 2407-2414.
13. Danchin N, Benetos A, Lopez-Sublet M, Demicheli T, Safar M, et al. (2004) Aortic pulse pressure is related to the presence and extent of coronary artery disease in men undergoing diagnostic coronary angiography: a multicenter study. Am J Hypertens 17 (2) (): 129-133.
14. Williams B, Lacy PS, Thom SM, Cruickshank K, Stanton A, et al. (2006) Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 113 (9) (): 1213-1225.
15. Roman MJ, Devereux RB, Kizer JR, Lee ET, Galloway JM, et al. (2007) Central pressure more strongly relates to vascular disease and outcome than does brachial pressure: the Strong Heart Study. Hypertension 50 (1) (): 197-203.
16. Chen X, Hassan MO, Jones JV, Sleight P, Floras JS, (1999) Baroreflex sensitivity and the blood pressure response to beta-blockade. J Hum Hypertens 13 (3) (): 185-190.
17. Chern CM, Hsu HY, Hu HH, Chen YY, Hsu LC, et al. (2006) Effects of atenolol and losartan on baroreflex sensitivity and heart rate variability in uncomplicated essential hypertension. J Cardiovasc Pharmacol 47 (2) (): 169-174.
18. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, et al. (2002) Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359 (9311) (): 995-1003.
19. Lindholm LH, Carlberg B, Samuelsson O, (2005) Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 366 (9496) (): 1545-1553.
20. Carlberg B, Samuelsson O, Lindholm LH, (2004) Atenolol in hypertension: is it a wise choice? Lancet 364 (9446) (): 1684-1689.
21. Bradley HA, Wiysonge CS, Volmink JA, Mayosi BM, Opie LH, (2006) How strong is the evidence for use of beta-blockers as first-line therapy for hypertension? Systematic review and meta-analysis. J Hypertens 24 (11) (): 2131-2141.
22. Morgan T, Lauri J, Bertram D, Anderson A, (2004) Effect of different antihypertensive drug classes on central aortic pressure. Am J Hypertens 17 (2) (): 118-123.
23. Cruickshank JM, (2007) Are we misunderstanding beta-blockers. Int J Cardiol 120 (1) (): 10-27.
24. Leopold G, Pabst J, Ungethum W, Buhring KU, (1986) Basic pharmacokinetics of bisoprolol, a new highly beta 1-selective adrenoceptor antagonist. J Clin Pharmacol 26 (8) (): 616-621.
25. Leopold G, (1986) Balanced pharmacokinetics and metabolism of bisoprolol. J Cardiovasc Pharmacol 8 Suppl 11: S16-20.
26. Pauca AL, O'Rourke MF, Kon ND, (2001) Prospective evaluation of a method for estimating ascending aortic pressure from the radial artery pressure waveform. Hypertension 38 (4) (): 932-937.
27. Wilkinson IB, Fuchs SA, Jansen IM, Spratt JC, Murray GD, et al. (1998) Reproducibility of pulse wave velocity and augmentation index measured by pulse wave analysis. J Hypertens 16 (12 Pt 2) (): 2079-2084.
28. Chen CH, Nevo E, Fetics B, Pak PH, Yin FC, et al. (1997) Estimation of central aortic pressure waveform by mathematical transformation of radial tonometry pressure. Validation of generalized transfer function. Circulation 95 (7) (): 1827-1836.
29. Wilkinson IB, MacCallum H, Flint L, Cockcroft JR, Newby DE, et al. (2000) The influence of heart rate on augmentation index and central arterial pressure in humans. J Physiol 525 Pt 1: 263-270.
30. Bos WJ, van Goudoever J, van Montfrans GA, van den Meiracker AH, Wesseling KH, (1996) Reconstruction of brachial artery pressure from noninvasive finger pressure measurements. Circulation 94 (8) (): 1870-1875.
31. Gizdulich P, Imholz BP, van den Meiracker AH, Parati G, Wesseling KH, (1996) Finapres tracking of systolic pressure and baroreflex sensitivity improved by waveform filtering. J Hypertens 14 (2) (): 243-250.
32. Gizdulich P, Prentza A, Wesseling KH, (1997) Models of brachial to finger pulse wave distortion and pressure decrement. Cardiovasc Res 33 (3) (): 698-705.
33. Westerhof BE, Gisolf J, Stok WJ, Wesseling KH, Karemaker JM, (2004) Time-domain cross-correlation baroreflex sensitivity: performance on the EUROBAVAR data set. J Hypertens 22 (7) (): 1371-1380.
34. Fox K, Ford I, Steg PG, Tendera M, Robertson M, et al. (2008) Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet 372 (9641) (): 817-821.
35. Wilkinson IB, Hall IR, MacCallum H, Mackenzie IS, McEniery CM, et al. (2002) Pulse-wave analysis: clinical evaluation of a noninvasive, widely applicable method for assessing endothelial function. Arterioscler Thromb Vasc Biol 22 (1) (): 147-152.
36. Asmar RG, Kerihuel JC, Girerd XJ, Safar ME, (1991) Effect of bisoprolol on blood pressure and arterial hemodynamics in systemic hypertension. Am J Cardiol 68 (1) (): 61-64.
37. Ong KT, Delerme S, Pannier B, Safar ME, Benetos A, et al. (2011) Aortic stiffness is reduced beyond blood pressure lowering by short-term and long-term antihypertensive treatment: a meta-analysis of individual data in 294 patients. J Hypertens 29 (6) (): 1034-1042.
38. Kahonen M, Ylitalo R, Koobi T, Turjanmaa V, Ylitalo P, (2000) Influences of nonselective, beta(1)-selective and vasodilatory beta(1)-selective beta-blockers on arterial pulse wave velocity in normotensive subjects. Gen Pharmacol 35 (4) (): 219-224.
39. De Cesaris R, Ranieri G, Filitti V, Andriani A, (1992) Large artery compliance in essential hypertension. Effects of calcium antagonism and beta-blocking. Am J Hypertens 5 (9) (): 624-628.
40. Abdelmawla AH, Langley RW, Szabadi E, Bradshaw CM, (1997) Bisoprolol attenuates noradrenaline- and phenylephrine-evoked venoconstriction in man in vivo. Br J Clin Pharmacol 44 (1) (): 61-68.
41. Abdelmawla AH, Langley RW, Szabadi E, Bradshaw CM, (1998) Comparison of the effects of nadolol and bisoprolol on noradrenaline-evoked venoconstriction in man in vivo. Br J Clin Pharmacol 45 (3) (): 271-276.
42. Uehara Y, Takada S, Hirawa N, Kawabata Y, Ohshima N, et al. (1994) Vasoconstrictors and renal protection induced by beta 1-selective adrenoceptor antagonist bisoprolol. J Cardiovasc Pharmacol 23 (6) (): 897-906.
43. Sun N, Hong T, Zhang R, Yang X, (2000) The effects of verapamil SR and bisoprolol on reducing the sympathetic nervous system's activity. Hypertens Res 23 (5) (): 537-540.
44. Dhakam Z, Yasmin, McEniery CM, Burton T, Brown MJ, et al. (2008) A comparison of atenolol and nebivolol in isolated systolic hypertension. J Hypertens 26 (2) (): 351-356.
45. Kumagai K, Suzuki H, Ichikawa M, Jimbo M, Nishizawa M, et al. (1996) Comparison of early and late start of antihypertensive agents and baroreceptor reflexes. Hypertension 27 (2) (): 209-218.
46. Minami N, Yoshikawa T, Kataoka H, Mori N, Nagasaka M, et al. (2003) Effects of exercise and beta-blocker on blood pressure and baroreflexes in spontaneously hypertensive rats. Am J Hypertens 16 (11 Pt 1) (): 966-972.
47. Le Coz F, Sauleman P, Poirier JM, Cuche JL, Midavaine M, et al. (1991) Oral pharmacokinetics of bisoprolol in resting and exercising healthy volunteers. J Cardiovasc Pharmacol 18 (1) (): 28-34.
48. van den Meiracker AH, Man in 't Veld AJ, van Eck HJ, Boomsma F, Schalekamp MA, (1988) Hemodynamic and hormonal adaptations to beta-adrenoceptor blockade. A 24-hour study of acebutolol, atenolol, pindolol, and propranolol in hypertensive patients. Circulation 78 (4) (): 957-968.
49. Fox K, Borer JS, Camm AJ, Danchin N, Ferrari R, et al. (2007) Resting heart rate in cardiovascular disease. J Am Coll Cardiol 50 (9) (): 823-830.